Clinical trials: Non-Hodgkin
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in…
- Trial name
- NCT04436107
- Testing
- Zanubrutinib, Lenalidomide
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- BeiGene
Advance Solid Tumors, Lymphoma, Non-Hodgkin
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
- Trial name
- PANGU-1 (NCT07864701)
- Testing
- JMBI-001 Tablets
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Chengdu Anticancer Bioscience, Ltd.
Non-Hodgkin's Lymphoma, Lymphoma, B-Cell
Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to investigate the antitumor effect and safety of the product for relapsed or refractory indolent B-cell non-Hodgkin's lymphomas.
- Conditions
- Non-Hodgkin's Lymphoma, Lymphoma, B-Cell, Lymphoma, Low-Grade
- Trial name
- NCT00220285
- Testing
- Zevalin (SH L 749 , BAY86-5128)
- Where
- 9 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Bayer
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- Soundtrack-E (NCT06564038)
- Testing
- Surovatamig, Prednisone (or equivalent), Rituximab
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 408 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00500058
- Testing
- SB-485232, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B Cell Lymphoma
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell…
- Trial name
- MINDway (NCT05222555)
- Testing
- Tafasitamab, Lenalidomide
- Where
- 62 sites in United States, Austria and 7 more
- Volunteers
- 53 people
- Sponsor
- Incyte Corporation
Adult B Acute Lymphoblastic Leukemia
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of Relapsed Refractory (R/R) adult acute lymphoblastic…
- Trial name
- NCT04626726
- Testing
- CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Non-Hodgkin's Lymphoma
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).
- Trial name
- NCT01180049
- Testing
- temsirolimus
- Where
- 31 sites in United States, Australia and 9 more
- Volunteers
- 101 people
- Sponsor
- Pfizer
Non-Hodgkins Lymphoma
Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma
The primary objective of this Phase 3 study is to definitively confirm the safety and efficacy of BiovaxId, an autologous tumor derived immunoglobulin idiotype vaccine, as measured by a significant prolongation of the period of…
- Trial name
- BiovaxID (NCT00091676)
- Testing
- FNHLId1, KLH + GM-CSF
- Volunteers
- 629 people
- Sponsor
- Biovest International
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Expanded Access to Tipifarnib
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL).
- Trial name
- Kuraoncology (NCT04809233)
- Testing
- Tipifarnib
- Sponsor
- Kura Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor.
- Trial name
- BRUIN CLL-321 (NCT04666038)
- Testing
- Pirtobrutinib, Idelalisib, Bendamustine
- Where
- 232 sites in United States, Australia and 22 more
- Volunteers
- 238 people
- Sponsor
- Loxo Oncology, Inc.
Alzheimer Disease, Dementia Alzheimers
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
The main purpose of this study is to evaluate safety, tolerability and immunogenicity of the vaccine ALZ-101 against Alzheimer's Disease. Patients diagnosed with early Alzheimer's will be included. The study have two parts.
- Conditions
- Alzheimer Disease, Dementia Alzheimers, Dementia, Mild
- Trial name
- NCT05328115
- Testing
- ALZ-101
- Where
- Finland
- Volunteers
- 33 people
- Sponsor
- Alzinova AB
Peripheral T Cell Lymphoma
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of GB226 for the treatment of relapsed and refractory peripheral T cell lymphoma…
- Trial name
- NCT03502629
- Testing
- GB226
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Genor Biopharma Co., Ltd.
Non-Hodgkin Lymphoma
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and…
- Trial name
- NCT06219356
- Testing
- GLB-002
- Where
- 13 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou GluBio Pharmaceutical Co., Ltd.
Relapsed/Refractory Peripheral T Cell Lymphoma
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.
- Trial name
- NCT06702605
- Testing
- XNW5004 tablets
- Volunteers
- 50 people
- Sponsor
- Evopoint Biosciences Inc.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase 1/2, multicenter, open-label study to evaluate the efficacy, and safety of various combinations with selinexor in participants with RR DLBCL. The study will be conducted in two phases: Phase 1 and 2.
- Trial name
- NCT04607772
- Testing
- Selinexor, Rituximab, Bendamustine
- Where
- 18 sites in United States
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Trial name
- NCT05370430
- Testing
- BAFFR-CAR T cells
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- PeproMene Bio, Inc.
Lymphoma, Non-Hodgkin, B-cell Lymphoma
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies.
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- BAF_FRontier-1 (NCT07101328)
- Testing
- LY4152199 - IV
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 215 people
- Sponsor
- Eli Lilly and Company
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
- Trial name
- NCT06149169
- Testing
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma…
- Conditions
- B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04594642
- Testing
- AZD0486 IV
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.